http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Rubius Therapeutics (RUBY) Announces Preclinical Data Supporting Lead Artificial Antigen Presenting Cell Program, RTX-321
-
Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Rubius Therapeutics to Announce Third Quarter 2019 Financial Results
-
Rubius Therapeutics to Announce Third Quarter 2019 Financial Results
-
Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences
-
Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences
-
Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference
-
Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference
-
Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
-
Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
-
Rubius Therapeutics to Announce Second Quarter 2019 Financial Results
-
Rubius Therapeutics to Announce Second Quarter 2019 Financial Results
-
Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy
-
Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy
-
Rubius Therapeutics (RUBY) Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs
-
Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs
-
Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs
-
Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference
-
Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference
-
Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
-
Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
-
Rubius Therapeutics to Announce First Quarter 2019 Financial Results
-
Rubius Therapeutics to Announce First Quarter 2019 Financial Results
-
Rubius Therapeutics to Participate in Jefferies 6th Annual IO Cell Therapy Summit
-
Rubius Therapeutics to Participate in Jefferies 6th Annual IO Cell Therapy Summit
-
Rubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual Meeting
-
Rubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual Meeting
-
Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates
-
Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates
-
Rubius Therapeutics (RUBY) Announces Natalie Holles to Board
-
Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer
-
Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer
-
Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results
-
Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results
-
Rubius Therapeutics (RUBY) Reports FDA Clearance of Investigational NDA for RTX-134 for Treatment of Phenylketonuria
-
Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
-
Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
-
Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting
-
Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting
-
Rubius Therapeutics to Participate at Upcoming Investor Conferences
-
Rubius Therapeutics to Participate at Upcoming Investor Conferences
-
Rubius Therapeutics (RUBY) Highlights Upcoming 2019 Milestones at J.P. Morgan Healthcare Conference
-
Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference
-
Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference
-
Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
Rubius Therapeutics, Inc. Secures $75 Million Loan Facility
-
Rubius Therapeutics, Inc. Secures $75 Million Loan Facility
-
Rubius Therapeutics Added to Nasdaq Biotechnology Index

